Detalles de la búsqueda
1.
The role of hemoadsorption in cardiac surgery - a systematic review.
BMC Cardiovasc Disord
; 24(1): 258, 2024 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38762715
2.
Intraoperative haemoadsorption for antithrombotic drug removal during cardiac surgery: initial report of the international safe and timely antithrombotic removal (STAR) registry.
J Thromb Thrombolysis
; 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38709456
3.
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding.
Eur Heart J
; 44(20): 1780-1794, 2023 05 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36988155
4.
Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry.
Crit Care
; 27(1): 243, 2023 06 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37337243
5.
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose.
Am Heart J
; 245: 19-28, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34736855
6.
Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial.
Catheter Cardiovasc Interv
; 100(1): 72-82, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35500171
7.
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study.
J Thromb Thrombolysis
; 54(3): 373-381, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36036856
8.
Comparison of the CytoSorb® 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study.
Minim Invasive Ther Allied Technol
; 31(7): 1058-1065, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35913784
9.
Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic Effects of Aspirin.
J Cardiovasc Pharmacol
; 78(2): 297-301, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33657049
10.
Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial.
Catheter Cardiovasc Interv
; 96(3): E377-E386, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31808295
11.
The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial.
Catheter Cardiovasc Interv
; 96(7): E688-E694, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31943717
12.
Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation.
J Thromb Thrombolysis
; 49(3): 337-343, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32080811
13.
Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial.
Catheter Cardiovasc Interv
; 93(7): 1374-1381, 2019 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31116908
14.
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study.
J Thromb Thrombolysis
; 48(4): 554-562, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31420787
15.
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.
Eur Heart J
; 39(46): 4112-4121, 2018 12 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30203006
16.
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
Circulation
; 133(3): 248-55, 2016 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-26762525
17.
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Circulation
; 134(10): 723-33, 2016 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27482008
18.
Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
Am Heart J
; 194: 73-82, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29223437
19.
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
Am Heart J
; 188: 147-155, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28577670
20.
Heparin or bivalirudin for non-primary PCI: Beware of neat and simple answers .
Catheter Cardiovasc Interv
; 90(3): 378-379, 2017 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28891164